Fanconi Anemia
Fludarabine without irradiation is effective in Fanconi anemia patients undergoing HSCT
Published in Blood Weekly, June 15th, 2006
According to a recently published report from the United States, "To potentially reduce late effects of malignancy, chronic graft-versus-host disease (GVHD), endocrinopathy, and infertility in patients with Fanconi anemia (FA) undergoing HLA-matched related donor hematopoietic cell transplantation (HCT), we developed a regimen using fludarabine (FLU), cyclophosphamide (CY), and antithymocyte globulin (ATG) followed by infusion of T-cell depleted (TCD) bone marrow (BM) or unmanipulated umbilical cord...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-06-15)
More Articles from Blood Weekly
- Bone Regeneration
PBMSCs may be a new source of circulating osteogenic stem cells for bone regeneration - Cord Blood
Study supports BioLife's approach to preserving umbilical cord blood-derived stem cells - Hematopoiesis
Lack of alpha 4 integrin expression in stem cells restricts competitive function and self-renewal - Stem Cell Transplantation
HSCT-related graft failure in thalassemia reduced by unrelated donor selection - Adverse Drug Reaction
Adverse effects of PI-containing regimens may put HIV-infected children at risk for CVD - Adverse Drug Reaction
Cytosolic 5'-nucleotidase I systemic chemotherapy is toxic - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
